PTC Therapeutics (PTCT) Director Michael Schmertzler Sells 25,000 Shares

What Happened
Michael Schmertzler, a director of PTC Therapeutics (PTCT), sold a total of 25,000 shares in open‑market transactions on August 19–20, 2026 for aggregate proceeds of approximately $1,805,412. The individual reported sales were: 5,335 shares at $72.86 ($388,708); 7,165 shares at $73.67 ($527,846); 9,419 shares at $70.78 ($666,677); 2,390 shares at $71.88 ($171,793); and 691 shares at $72.92 ($50,388). These were sales (not purchases), which are often routine disposition transactions.

Key Details

• Transaction dates: Aug 19–20, 2026; Form 4 filed Aug 21, 2026 (appears timely).
• Total shares sold: 25,000; total proceeds: ~$1.81 million.
• Reported prices reflect weighted averages of multiple trades; filing footnotes state the seller will provide per‑trade breakdowns to the SEC, issuer or security holders on request.
• Sales were effected pursuant to a written Rule 10b5‑1 plan adopted May 14, 2026 by Section Six Partners, L.P., of which Schmertzler is a general partner and limited partner.
• Shares sold are reported as held by Section Six Partners, L.P.; Schmertzler disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context
These transactions were disposals under a prearranged 10b5‑1 plan; such plans allow insiders to sell shares according to a preset schedule and are commonly used to avoid timing concerns. Sales do not necessarily signal a change in conviction about the company—retail investors often consider purchases as stronger signals of insider sentiment.